Navigation Links
NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
Date:4/22/2009

DENVER and SAN CARLOS, Calif., April 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented data today at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior antitumor activity, as well as greater and sustained exposure in plasma and tumor tissue, over docetaxel in preclinical models.

In a comparative study of NKTR-105 and docetaxel, NKTR-105 treatment significantly delayed tumor growth as compared to docetaxel (122% v. 48%), which was associated with greater and sustained tumor exposure to docetaxel after NKTR-105 administration. Treatment with NKTR-105 increased docetaxel concentrations in tumors (0.4 to 4-fold higher) and resulted in an improved time-concentration profile (2-fold greater) as compared to docetaxel in a non-small cell lung (H460) mouse xenograft model.

"The encouraging antitumor activity and unique pharmacokinetic profile of NKTR-105 in these data support our ongoing Phase 1 study in patients with refractory solid cancers," said Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer. "We believe NKTR-105 has the potential to offer improved efficacy as well as improved safety and tolerability due to its prolonged half-life and increased uptake by tumor tissue relative to docetaxel. We are excited about the drug's potential to significantly expand therapeutic options for oncologists and patients."

In previous preclinical studies, NKTR-105 demonstrated superior antitumor activity with no neutropenia in multiple tumor models, indicating that NKTR-105 may enable sustained therapeutic levels of docetaxel without the myelosuppression that is a dose-limiting toxicity for this widely-used cancer therapy.

NKTR-105 is currently
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
2. Fish researcher demonstrates first non-visual feeding by African cichlids
3. Harris Corporation Demonstrates Global Medical Imagery Access, Sharing and Collaboration Capabilities
4. Edmond Scientific Company Demonstrates RHIO/HIE Data Security and Privacy Solution for the NHIN at Annual HIMSS Conference, Chicago 09
5. Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
6. Siemens Demonstrates Workflow Efficiency in Echocardiography at ACC 2009
7. Siemens Demonstrates Flash Speed, Lowest Dose at ACC 2009
8. New published study demonstrates over-the-counter device lowers blood pressure in diabetic patients
9. MU researcher demonstrates non-traditional therapy is effective as pain management
10. IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
11. Bay Valleys French Style Dressing Demonstrates Z Trims Value to Private Label and Store Brands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... York (PRWEB) May 20, 2013 The nationwide ... study has found that magnetic resonance imaging (MRI) can be ... of whether or not patients are experiencing symptoms. According ... Journal of Bone & Joint Surgery, MRI detected synovitis (tissue ... patients suffering symptoms due to mechanical causes, the detection rate ...
(Date:5/20/2013)... A child whose mother lived near heavy traffic while ... respiratory infection before the age of 3, a new ... 1,300 pairs of mothers and infants from eastern Massachusetts. ... first trimester of pregnancy at some point between 1999 ... lived within 100 meters (about 110 yards) from a ...
(Date:5/20/2013)... transforms the sweet flavor of orange juice into something ... phenomenon in colorful, animated detail check the ... Bytesize Science video series at http://www.BytesizeScience.com ... explains that the mainstay ingredients in toothpaste include a ... When you brush your teeth, SLS produces the foamy ...
(Date:5/20/2013)... Join Seva Foundation in celebrating its 35th Anniversary with ... Fine Arts Theater in San Francisco, featuring: Snatam ... with host Wavy Gravy. All proceeds will benefit Seva Foundation’s ... seats are $40 & $55, VIP tickets are $150 and ... row seat at the show. Tickets are available through ...
(Date:5/20/2013)... May 20, 2013 Cliff Lake Dental Care is ... accommodate patient schedules when visiting the dentist office . The ... and life schedule. , Here are the new office hours: Mondays- ... Wednesday – 8 a.m. to 1 p.m. and 2-5 p.m., Thursdays ... the office will be open to take appointments only. Cliff Lake ...
Breaking Medicine News(10 mins):Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4Health News:Living Near Major Roadways in Pregnancy Tied to Respiratory Woes in Children 2Health News:Memorial Day Kirtan Concert Palace of Fine Arts Theater in San Francisco Featuring: Snatam Kaur, Jai Uttal, C.C. White & Shimshai with host Wavy Gravy,May 27th 7:00 PM 2Health News:Cliff Lake Dental Care Announces Office Hours Change 2
... someday get a personalized menu of foods to eat during ... new research at Washington University// School of Medicine in St. ... a way to discover how genes and diet interact to ... know they are pregnant, the development of the fetus' organs ...
... that Maoris carry a "warrior" gene which make them ... terming such claims// as dangerous and inflammatory. ... Environmental Science and Research, Dr Rod Lea and his ... oxidase, often referred to as the warrior gene, which ...
... centre employees between the ages of 19 to 31 years ... insulin malfunction.// ,The Delhi Diabetes Research Centre had ... explained that the epidemic of diabetes has for a very ... that there is now an increasing trend where in younger ...
... mothers who took the anti-miscarriage drug diethylstilbestrol at the time ... to a new study published in the August issue of ... DES daughters over age 40 had 1.9 times the risk ... the drug. ,They also found that the relative ...
... Indian worker in Bahrain died, days before he was to ... ,A free visa worker, Muthanna Poshanna, 46, died following ... according to a report in the Gulf Daily News newspaper. ... that they were waiting for word from Poshanna's family in ...
... got the Oman government's permission to carry out surgeries ... the group's new centre in the Omani capital Muscat. ... the green signal to start our operation theatres, Intensive ... report in the Times of Oman newspaper quoted V.T. ...
Cached Medicine News:Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3Health News:Warrior Gene Claims Slammed by Maori 2Health News:Warrior Gene Claims Slammed by Maori 3Health News:Studies Find That Call Centre Employees Could Be More Prone to Diabetes 2Health News:"DES Daughters" Have High Risk Of Breast Cancer 2Health News:"DES Daughters" Have High Risk Of Breast Cancer 3
(Date:5/20/2013)... , May 20, 2013 /PRNewswire-iReach/ -- Today ... Dr. Christine Ginocchio discussed ... solution for rapid identification of microorganisms producing bloodstream ... and Chief of the Division of Infectious Disease ... 2nd largest not-for-profit, non-sectarian health system. ...
(Date:5/20/2013)... NEW YORK , May 20, 2013  Echo ... Rule 2.5 of the Irish Takeover Rules (the "Announcement"), ... Corporation, plc (NYSE: ELN ) to $12.50 ... financed, cash confirmed and not conditional on due diligence.  ... eliminated.  Royalty Pharma has reserved the right to waive ...
(Date:5/20/2013)...   Life Technologies Corporation (NASDAQ: ... Dx and 3500xL Dx Genetic Analyzers have been approved ... in Mexico for diagnostic use.  ... capabilities to serve the clinical end market in ... -based solutions.  The Applied Biosystems™ ...
Breaking Medicine Technology:Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3
... Therapeutics, Division of Janssen Products, LP, announced today ... issued a Complete Response letter for a Supplemental ... of PREZISTA® (darunavir). PREZISTA is approved for ... -- for the treatment of human immunodeficiency virus (HIV-1) ...
... 29, 2012 Avanir Pharmaceuticals, Inc. (NASDAQ: ... of the company at the Jefferies 2012 Global Healthcare Conference in ... York, NY , Presentation date: Monday, June 4, 2012 ... A live webcast and 30-day archive of these presentations will be ...
Cached Medicine Technology:FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 2FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 3FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 4FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 5FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 6FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 7
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: